HK Stock Market Move | JACOBIO-B (01167) rose over 13% in early trading, with a net profit exceeding 600 million yuan in the first half of the year, turning losses from the same period last year into profits.

JACOBIO-B (01167) surged over 13% in early trading. As of the time of writing, it has risen 13.08%, trading at HKD 5.835, with a transaction volume of HKD 13.1982 million. In news, Jacky Bioscience has released its interim results, reporting revenue of HKD 731 million, a year-on-year increase of 1500.5%. The profit attributable to equity holders of the company was HKD 601 million, compared to a loss of HKD 58.994 million in the same period last year, achieving a turnaround to profitability. The announcement stated that the revenue growth was primarily due to a strategic collaboration with AstraZeneca AB for the global research and development, production, and commercialization of JAB-23E73; and the signing of external licensing and service agreements with Shanghai Allist Pharmaceuticals Co., Ltd. for the research, production, and commercialization of Arica and sitneprotafib.